OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
Stay tuned for more details, and feel free to share your thoughts below. Let’s make this community even stronger!
Questions about CRS and HIPEC
Hi there,
I haven't been on this forum for a while but I have some questions about HIPEC. I was diagnosed with stage 2B high grade endometrial ovarian cancer in October 2023. I had surgery in December (all gynecological parts plus omentum and appendix removed) and started with carboplatin and paclitaxel late January 2024. In April the CT scan showed that I did have peritoneal nodules that were missed in previous CT scan so I was reclassified as 3B. Despite the nodules growing throughout the six courses of chemotherapy, my oncologist thought it would be worthwhile to continue for three more cycles. The PET scan six weeks after nine courses of chemo ended showed progression of disease and I was deemed carboplatin refractory. I am now on gemcitabine and bevacizumab.
I have talked to a researcher in Ontario who thinks HIPEC (using mitomycin, maybe) may be of value to me but my oncologist dismisses it out of hand. If anyone can give me any insight into why that may be the case, I would appreciate it. I live in B.C. and I find B.C. cancer is very protocol based.
Thanks for this